Despite Carlumab’s lack of efficacy in treating progressive idiopathic pulmonary fibrosis (IPF), these findings suggest that newer agents are needed to suppress CCL2-mediated signaling more effectively. Here, CCL2 is linked to pulmonary fibrosis.